Albaugh and Marrone Bio Innovations Sign Exclusive Seed Treatment Agreement for a Microbial Biopesticide Product

DAVIS, Calif.--()--Albaugh, LLC, a leading provider of crop protection products and seed treatment technology and Marrone Bio Innovations, Inc. (NASDAQ:MBII) (MBI), a leading provider of effective and environmentally responsible pest management and plant health products, announced today the companies have signed an exclusive agreement to develop and market one of MBI’s microbial products, a proprietary microbial biopesticide with insecticidal and nematicidal properties, for seed treatment applications.

Dr. Pam Marrone, Founder and Chief Executive Officer of Marrone Bio Innovations, commented, “We are pleased to add Albaugh to our growing network of strategic partners. The combination of their state-of-the-art seed treatment technology and expertise and our proprietary microbial technology is expected to yield new, innovative solutions for growers. We are very excited about the potential to commercialize new, globally-relevant seed treatment applications. We are confident, given MBI’s three years of field research that demonstrates efficacy against a broad spectrum of pests, we will quickly reveal the value of this important partnership.”

Albaugh Seed Treatment technology is developing a robust portfolio for the seed treatment market. “This agreement strengthens our commitment to address customer’s needs and expand our product offers and concepts,” says Chris Zita, Director of Seed Treatments, North America. “Our goal is to provide seed treatment technology that is driven by innovation, performance and value and this agreement is a great example of our focus and drive to delivery on that strategy.”

“This strategic partnership is the first step to helping us deliver novel solutions to the seed treatment industry,” stated Albaugh’s Director of Global Proprietary Projects Chad Shelton. “Delivering a new biopesticide seed treatment with combined activity as an insecticide and nematicide that delivers value to the growers will be the first exciting result of this collaboration.”

The agreement covers all crops for seed treatment in the United States and Canada.

About ALBAUGH, LLC

Albaugh, LLC is the largest global privately-held producer of post-patent herbicides, fungicides, insecticides and plant-growth regulators. Albaugh has leading market positions in four of the most widely-used post-patent agrochemicals worldwide -- glyphosate, 2,4-D, atrazine and dicamba - with direct market presence in the USA, Canada, Mexico, Brazil, Argentina and Europe.”

Please visit http://albaughllc.com.

Albaugh, LLC Contacts:

Chris Zita, Director of Seed Treatments, North America

(541) 215-5063

chrisz@albaughllc.com

Chad Shelton, Director of Global Proprietary Projects

(509) 385-4140

chads@albaughllc.com

About Marrone Bio Innovations

Smart. Natural. Solutions.

Marrone Bio Innovations, Inc. (NASDAQ: MBII) strives to lead the movement to a more sustainable world through the discovery, development and promotion of biological products for pest management and plant health. Our effective and environmentally responsible solutions help customers operate more sustainably while controlling pests, improving plant health, and increasing crop yields. We have four products for agriculture on the market (Regalia®, Grandevo®, Venerate® and Majestene®), and also distribute Bio-tam 2.0® for Isagro USA in the western U.S. MBI also markets Zequanox® for invasive mussels for water markets. We also have a proprietary discovery process, a rapid development platform, and a robust pipeline of pest management and plant health product candidates. At Marrone Bio Innovations we are dedicated to pioneering better biopesticides that support a better tomorrow for users around the globe. For more information, please visit www.marronebio.com.

Marrone Bio Innovations Forward Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI’s views as of any subsequent date. Examples of such statements include statements regarding sales of the Company’s products, including GRANDEVO and VENERATE, in Mexico and other markets, the potential benefits of the Company’s products, and MBI’s efforts with respect to expansion of its product labels. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company's control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including consumer, regulatory and other factors affecting demand for the Company’s products, any difficulty in marketing MBI’s products in Mexico, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers, and adverse decisions by regulatory agencies and other relevant third parties. Additional information that could lead to material changes in MBI’s performance is contained in its filings with the SEC. MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of new information, future events or otherwise.

Contacts

Marrone Bio Innovations:
Nancy M. Hood, VP Marketing
Telephone: +1 (530) 302-8290
Email: nhood@marronebio.com
or
MBI Investor:
James Palczynski, ICR
Telephone: +1 (203) 682-8229
Email: James.Palczynski@icrinc.com

Release Summary

Albaugh and Marrone Bio Innovations Sign Exclusive Seed Treatment Agreement for a Microbial Biopesticide Product

Contacts

Marrone Bio Innovations:
Nancy M. Hood, VP Marketing
Telephone: +1 (530) 302-8290
Email: nhood@marronebio.com
or
MBI Investor:
James Palczynski, ICR
Telephone: +1 (203) 682-8229
Email: James.Palczynski@icrinc.com